Seminar for Neurotrauma and Diseases, Mon., Oct. 14

Event Date: October 14, 2024
Hosted By: Center for Paralysis Research
Time: 4:00 p.m.
Location: DLR 131
Priority: No
School or Program: Non-Engineering
College Calendar: Show
Negin Ashki
Negin Ashki, MD, PhD, Senior Medical Director, Global/US Medical Affairs - Oncology, Eli Lilly and Company
Negin Ashki, MD, PhD, Senior Medical Director, Global/US Medical Affairs - Oncology, Eli Lilly and Company, will present "A Journey from Basic Neuroscientist to Clinical Oncologist to Leading Lilly Oncology/Hematology Drug Development Efforts" on Monday, October 14, at 4:00 p.m. in DLR 131.

This seminar is part of the Seminar for Neurotrauma and Diseases series, sponsored by Plexon and the Purdue Center for Paralysis Research.

Bio:  Dr. Negin Ashki, MD PhD., completed her PhD degree in Neuroscience at the University of Western Ontario, Canada. Her thesis added support to the concept that immune-mediated axonal conduction failure contributes to reversible neurologic deficits following neurotrauma and aided in understanding clinical phenomena such as spinal shock and neurologic recovery. This work resulted in numerous 1st author and co-author peer-reviewed manuscripts. 

Following completion of medical school and residency training in Canada, Negin completed a Fellowship in Oncology/Hematology at University of Los Angeles (UCLA), California. At UCLA, her translational research focused on regulatory role of epithelial membrane protein 2 (EMP2) in T cells and macrophages. To further build on this body of work, Negin led the development of anti-EMP2 monoclonal antibody and investigated its therapeutic efficacy in combination with checkpoint inhibitors in human tumor xenograft models of triple negative breast cancer. This work resulted in numerous peer-reviewed publications and Negin was awarded Excellence in Research Award as a Fellow. 
Following Fellowship, Negin joined Eli Lilly as the Medical Lead of Oncology for the Canadian Affiliate where she led the launch of Verzenio for treatment of metastatic and early breast cancer and Retevmo for treatment of RET positive lung and thyroid cancer. Currently she is the Sr. Medical Director of Oncology within the Early Phase Global Patient Safety/Clinical Development Research Program.  

2024-10-14 16:00:00 2024-10-14 17:00:00 America/Indiana/Indianapolis Seminar for Neurotrauma and Diseases, Mon., Oct. 14 Negin Ashki, MD, PhD, Senior Medical Director, Global/US Medical Affairs - Oncology, Eli Lilly and Company, will present "A Journey from Basic Neuroscientist to Clinical Oncologist to Leading Lilly Oncology/Hematology Drug Development Efforts" on Monday, October 14, at 4:00 p.m. in DLR 131. DLR 131